VivoSeq
Oncology

Breast Ductal Carcinoma in Situ

19

Pipeline Programs↗

2

Active Trials↗

12

Companies Involved↗

Breast Ductal Carcinoma in Situ is an emerging landscape with 19 programs across 12 companies. The most active players are Merck & Co., AstraZeneca, Fresenius Kabi Oncology Ltd.. 8 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

Phase 2S

San Diego Pacific Oncology & Hematology Associates

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3A

Avyxa

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

16 of 20 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody210%Protein / enzyme15%Peptide15%

Small molecule leads; the ring shows all 20 classified programs, each share of the total. Modality classified for 100% of 20 pipeline programs.

Analysis

Trial Status

4

clinical trials

Enrolling by invitation1 · 25%
Unknown status1 · 25%
Terminated1 · 25%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
Enrolling by invitation·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06843681·54 enrolled
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
Unknown status·NNational Taiwan University Hospital·Phase 3·NCT04046159·810 enrolled
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
Terminated·UUniversity of Southern California·Phase 2·NCT00183963·4 enrolled
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT01272037·5,018 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)